Which antiretroviral combinations should be avoided by patients coinfected with HIV and hepatitis C virus (HCV)?

Updated: Oct 07, 2019
  • Author: Vinod K Dhawan, MD, FACP, FRCPC, FIDSA; Chief Editor: BS Anand, MD  more...
  • Print

Avoid interrupting antiretroviral therapy to allow HCV treatment.

Avoid the use of elbasvir/grazoprevir or simeprevir with cobicistat, efavirenz, etravirine, nevirapine, or any HIV protease inhibitor.

Avoid the use of glecaprevir/pibrentasvir with atazanavir, ritonavir-containing antiretroviral regimens, efavirenz, or etravirine.

Avoid the use of sofosbuvir/velpatasvir with efavirenz, etravirine, or nevirapine.

Avoid the use of sofosbuvir/velpatasvir/voxilaprevir with ritonavir-boosted atazanavir, efavirenz, etravirine, or nevirapine.

Avoid the use of sofosbuvir-based regimens with tipranavir.

Avoid the use of paritaprevir/ritonavir/ombitasvir plus cobicistat, dasabuvir with darunavir, efavirenz, etravirine, nevirapine, rilpivirine, ritonavir-boosted lopinavir, or ritonavir-boosted tipranavir.

Avoid the use of paritaprevir/ritonavir/ombitasvir, with or without dasabuvir, in HIV/HCV-coinfected individuals who are not taking antiretroviral therapy.

Avoid the use of ribavirin with didanosine, stavudine, or zidovudine.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!